Sansure Biotech Inc.
Символ: 688289.SS
SHH
20.46
CNYПазарна цена днес
30.4998
Съотношение P/E
0.0000
Коефициент PEG
11.73B
MRK Cap
- 0.03%
Доходност на DIV
Sansure Biotech Inc. (688289-SS) финансови отчети
Баланс
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 19413.47 | 4781.8 | 5663.8 | 4682.7 | |||||||
balance-sheet.row.short-term-investments | 4899.6 | 548.3 | 2451.2 | 2046.5 | |||||||
balance-sheet.row.net-receivables | 3370.7 | 732.8 | 1472.7 | 894.1 | |||||||
balance-sheet.row.inventory | 1438.13 | 376.6 | 355.3 | 369.5 | |||||||
balance-sheet.row.other-current-assets | 188.44 | 58.4 | 33.6 | 20 | |||||||
balance-sheet.row.total-current-assets | 24410.75 | 5949.6 | 7525.4 | 5966.2 | |||||||
balance-sheet.row.property-plant-equipment-net | 3864.39 | 1055.2 | 785.3 | 481 | |||||||
balance-sheet.row.goodwill | 29.47 | 7.7 | 0 | 0 | |||||||
balance-sheet.row.intangible-assets | 908.39 | 328 | 84.4 | 45.6 | |||||||
balance-sheet.row.goodwill-and-intangible-assets | 937.86 | 335.6 | 84.4 | 45.6 | |||||||
balance-sheet.row.long-term-investments | 259.32 | 974.3 | -1793.8 | -1533.2 | |||||||
balance-sheet.row.tax-assets | 277.3 | 73.8 | 69.6 | 25 | |||||||
balance-sheet.row.other-non-current-assets | 4000.45 | 65.6 | 2502.8 | 2105.8 | |||||||
balance-sheet.row.total-non-current-assets | 9339.32 | 2504.6 | 1648.3 | 1124.1 | |||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-assets | 33750.07 | 8454.2 | 9173.8 | 7090.4 | |||||||
balance-sheet.row.account-payables | 1680.85 | 468.7 | 791.4 | 258.7 | |||||||
balance-sheet.row.short-term-debt | 161.33 | 77.2 | 14.3 | 8.5 | |||||||
balance-sheet.row.tax-payables | 136.64 | 17.7 | 216.4 | 101.3 | |||||||
balance-sheet.row.long-term-debt-total | 434.36 | 18.2 | 13.6 | 6.4 | |||||||
Deferred Revenue Non Current | 125.25 | 32.5 | 30.5 | 25.7 | |||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 202.41 | - | - | - | |||||||
balance-sheet.row.other-current-liab | 603.52 | 340.5 | 712.9 | 2.4 | |||||||
balance-sheet.row.total-non-current-liabilities | 761.97 | 77.7 | 89.3 | 45.1 | |||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.capital-lease-obligations | 59.8 | 18.2 | 13.6 | 6.4 | |||||||
balance-sheet.row.total-liab | 4086.73 | 996.8 | 1661 | 709 | |||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.common-stock | 2353.84 | 588.5 | 588.5 | 400 | |||||||
balance-sheet.row.retained-earnings | 19890.19 | 4882.7 | 5077.1 | 3820 | |||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 5231.51 | 395.2 | 377.4 | 294 | |||||||
balance-sheet.row.other-total-stockholders-equity | 1682.68 | 1334.9 | 1457.7 | 1854.9 | |||||||
balance-sheet.row.total-stockholders-equity | 29158.21 | 7201.3 | 7500.6 | 6368.9 | |||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 33750.07 | 8454.2 | 9173.8 | 7090.4 | |||||||
balance-sheet.row.minority-interest | 472.64 | 223.6 | 12.2 | 12.4 | |||||||
balance-sheet.row.total-equity | 29630.85 | 7424.9 | 7512.8 | 6381.3 | |||||||
balance-sheet.row.total-liabilities-and-total-equity | 33750.07 | - | - | - | |||||||
Total Investments | 5158.91 | 1522.6 | 657.4 | 513.2 | |||||||
balance-sheet.row.total-debt | 611.49 | 95.4 | 27.9 | 14.9 | |||||||
balance-sheet.row.net-debt | -13902.38 | -4138 | -3184.7 | -2621.3 |
Отчет за паричните потоци
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 384.73 | 1936.7 | 2242.5 | 2616.6 | ||||||
cash-flows.row.depreciation-and-amortization | 16.6 | 89.1 | 53.9 | 26.7 | ||||||
cash-flows.row.deferred-income-tax | -65.27 | -40 | -8.1 | -4.6 | ||||||
cash-flows.row.stock-based-compensation | 14.27 | 60.8 | 5.6 | 4.6 | ||||||
cash-flows.row.change-in-working-capital | 256.09 | 203.3 | -402.1 | -50.4 | ||||||
cash-flows.row.account-receivables | 376.54 | -496.5 | -304.1 | -419.4 | ||||||
cash-flows.row.inventory | -78.3 | -282.1 | -93 | -212.1 | ||||||
cash-flows.row.account-payables | 0 | 496.5 | 3.1 | 585.7 | ||||||
cash-flows.row.other-working-capital | -42.16 | 485.4 | -8.1 | -4.6 | ||||||
cash-flows.row.other-non-cash-items | -214.09 | 308.9 | -14.8 | 49.4 | ||||||
cash-flows.row.net-cash-provided-by-operating-activities | 50.78 | 0 | 0 | 0 | ||||||
cash-flows.row.investments-in-property-plant-an-equipment | -335.04 | -558.8 | -372.9 | -108.7 | ||||||
cash-flows.row.acquisitions-net | 47.75 | -11.6 | 15.9 | 115 | ||||||
cash-flows.row.purchases-of-investments | -6118.59 | -12140.6 | -7880 | -3725 | ||||||
cash-flows.row.sales-maturities-of-investments | 8246.29 | 11591.1 | 7125.6 | 2111.3 | ||||||
cash-flows.row.other-investing-activites | -136.85 | -46.9 | -0.9 | -108.7 | ||||||
cash-flows.row.net-cash-used-for-investing-activites | 1881.15 | -1166.7 | -1112.2 | -1716 | ||||||
cash-flows.row.debt-repayment | -399.13 | -17.2 | -55 | -55 | ||||||
cash-flows.row.common-stock-issued | 0 | 274.6 | 200 | 0 | ||||||
cash-flows.row.common-stock-repurchased | -244.98 | -257.4 | -200 | 0 | ||||||
cash-flows.row.dividends-paid | -405.17 | -656.9 | -439.9 | -301.3 | ||||||
cash-flows.row.other-financing-activites | 410.54 | -259 | -193.7 | 1966.2 | ||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -103.53 | -915.9 | -688.6 | 1609.9 | ||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.96 | -10 | -34.3 | -44.6 | ||||||
cash-flows.row.net-change-in-cash | 1865.05 | 466.2 | 42 | 2491.6 | ||||||
cash-flows.row.cash-at-end-of-period | 14448.39 | 3099.1 | 2632.8 | 2590.8 | ||||||
cash-flows.row.cash-at-beginning-of-period | 12583.34 | 2632.8 | 2590.8 | 99.2 | ||||||
cash-flows.row.operating-cash-flow | 50.78 | 2558.9 | 1877.1 | 2642.3 | ||||||
cash-flows.row.capital-expenditure | -335.04 | -558.8 | -372.9 | -108.7 | ||||||
cash-flows.row.free-cash-flow | -284.26 | 2000.1 | 1504.2 | 2533.6 |
Ред за отчет за приходите
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 1197.62 | 1002.5 | 6450.4 | 4514.5 | |||||||
income-statement-row.row.cost-of-revenue | 324.81 | 381.8 | 2655.4 | 1279 | |||||||
income-statement-row.row.gross-profit | 872.81 | 620.7 | 3795 | 3235.5 | |||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.research-development | 195.53 | - | - | - | |||||||
income-statement-row.row.selling-general-administrative | 145.35 | - | - | - | |||||||
income-statement-row.row.selling-and-marketing-expenses | 412.82 | - | - | - | |||||||
income-statement-row.row.other-expenses | -1.78 | 10.6 | 95.5 | 44.5 | |||||||
income-statement-row.row.operating-expenses | 808.25 | 638.7 | 1262.2 | 666.9 | |||||||
income-statement-row.row.cost-and-expenses | 1133.06 | 1020.5 | 3917.5 | 1945.9 | |||||||
income-statement-row.row.interest-income | -1.65 | 54.7 | 48.4 | 32.5 | |||||||
income-statement-row.row.interest-expense | 7.51 | 2.4 | 2.1 | 0.8 | |||||||
income-statement-row.row.selling-and-marketing-expenses | 412.82 | - | - | - | |||||||
income-statement-row.row.total-other-income-expensenet | 47.65 | 450.7 | -23.9 | -5.6 | |||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||
income-statement-row.row.other-operating-expenses | -1.78 | 10.6 | 95.5 | 44.5 | |||||||
income-statement-row.row.total-operating-expenses | 47.65 | 450.7 | -23.9 | -5.6 | |||||||
income-statement-row.row.interest-expense | 7.51 | 2.4 | 2.1 | 0.8 | |||||||
income-statement-row.row.depreciation-and-amortization | -18.56 | 136.8 | 290.8 | -20.7 | |||||||
income-statement-row.row.ebitda-caps | 381.57 | - | - | - | |||||||
income-statement-row.row.operating-income | 400.13 | -18 | 2339.8 | 2621.8 | |||||||
income-statement-row.row.income-before-tax | 447.78 | 432.6 | 2315.9 | 2616.2 | |||||||
income-statement-row.row.income-tax-expense | 70.79 | 62.3 | 379.2 | 373.7 | |||||||
income-statement-row.row.net-income | 384.73 | 363.7 | 1936.8 | 2242.7 |
Често задавани въпроси
Какво е Sansure Biotech Inc. (688289.SS) общи активи?
Sansure Biotech Inc. (688289.SS) общите активи са 8454204974.000.
Какъв е годишният приход на предприятието?
Годишните приходи са 760245723.000.
Какъв е маржът на печалбата на предприятието?
Маржът на печалбата на фирмата е -0.496.
Какъв е свободният паричен поток на компанията?
Свободният паричен поток е -0.496.
Какъв е маржът на нетната печалба на предприятието?
Маржът на нетната печалба е 0.321.
Какъв е общият приход на предприятието?
Общият приход е 0.334.
Каква е Sansure Biotech Inc. (688289.SS) нетна печалба (нетен доход)?
Нетната печалба (нетният доход) е 363721131.000.
Какъв е общият дълг на фирмата?
Общият дълг е 95444005.000.
Какъв е броят на оперативните разходи?
Оперативните разходи са 638676546.000.
Какъв е броят на паричните средства на фирмата?
Паричните средства на предприятието са 4330820791.000.